HOOKIPA Pharma Inc HOOK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if HOOK is a good fit for your portfolio.
News
-
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
-
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
-
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
-
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
Trading Information
- Previous Close Price
- $0.76
- Day Range
- $0.74–0.78
- 52-Week Range
- $0.41–2.05
- Bid/Ask
- $0.77 / $0.78
- Market Cap
- $76.20 Mil
- Volume/Avg
- 99,206 / 546,237
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.90
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 179
- Website
- https://www.hookipapharma.com
Comparables
Valuation
|
Metric
|
HOOK
|
CLDX
|
CGEM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.91 | 5.10 | 1.61 |
Price/Sales | 3.90 | 275.86 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
HOOK
|
CLDX
|
CGEM
|
|---|---|---|---|
Quick Ratio | 3.25 | 13.69 | 16.60 |
Current Ratio | 3.50 | 13.87 | 17.07 |
Interest Coverage | −271.89 | — | — |
Quick Ratio
HOOK
CLDX
CGEM
Profitability
|
Metric
|
HOOK
|
CLDX
|
CGEM
|
|---|---|---|---|
Return on Assets (Normalized) | −40.97% | −30.49% | −24.60% |
Return on Equity (Normalized) | −72.06% | −33.19% | −25.95% |
Return on Invested Capital (Normalized) | −72.10% | −32.85% | −29.67% |
Return on Assets
HOOK
CLDX
CGEM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Twqsltld | Fbk | $559.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xdxrphyz | Cxwfrb | $102.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hwkyzxssx | Nknmyx | $98.6 Bil | |
MRNA
| Moderna Inc | Vtwwsjjtg | Fjp | $41.0 Bil | |
ARGX
| argenx SE ADR | Bhpbbdbp | Fpk | $22.6 Bil | |
BNTX
| BioNTech SE ADR | Dwmgxvn | Mmhhp | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Dlbylgb | Lytdc | $18.8 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mtqnssw | Zfsxpf | $17.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Bvhnvzncm | Hcrcml | $12.6 Bil | |
INCY
| Incyte Corp | Rvrvwygsc | Nffldx | $12.0 Bil |